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CObjective: To assess the measurement equivalence of an interactive
voice response (IVR) version of the EQ-5D with the original paper
version. Methods: Subjects were randomly assigned to: 1) paper then
VR, or 2) IVR then paper and asked to complete the questionnaire two
ays apart. The analyses tested mean differences (repeated measures
nalysis of variance) and reliability (intraclass correlation coefficient
ICC]). Equivalence of the means was established if the 95% confidence
nterval (CI) of the mean difference was within the minimally impor-
ant difference interval:0.035 to 0.035 for the EQ-5D index and3 to 3
for the visual analog scale (EQ VAS). ICC adequacy was tested by com-
paring the ICC 95% lower CI with a critical value of 0.70. Results: The
analyses included 113 subjects for the index and 109 subjects for the
EQ VAS. For the index, the adjusted means of the paper and IVR
versions were 0.789  0.016 and 0.798  0. 017, respectively. The 95% O
atien
al So
doi:10.1016/j.jval.2011.03.001I of the mean difference was 0.024 to 0.006, within the equiva-
ence interval. The ICC was 0.894 (95% lower CI 0.857), significantly
reater than 0.70. For the EQ VAS, the adjusted means were 71.94 
.87 for paper and 74.63  1.79 for IVR. The 95% CI of the mean
ifference was 4.347 to 1.049, partially within the equivalence
nterval. The ICC was 0.887 (95% lower CI 0.840), significantly greater
han 0.70. Conclusions: The results provide evidence that the EQ-5D
cores on the IVR versionwere sufficiently equivalent to those obtained
n the paper version.
eywords: electronic data capture, EQ-5D, equivalence, interactive
oice response, measurement IVR.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Most patient-reported outcome measures (e.g., symptom experi-
ence, health status, and health-related quality of life) were origi-
nally developed to be administered via paper and pencil. Data
were then entered into a database for analysis through manual
(keyed/typed) data entry or optical scanning. Advances in technol-
ogy have provided more efficient methods for self- or patient-re-
ported outcome (PRO) data collection and database creation. Al-
though there are clear advantages to collecting data electronically,
equivalence between the alternative modes of data collection must
beestablished. Foruse in clinical trials, theUSFoodandDrugAdmin-
istration is expecting to see such evidence when a PRO measure is
adapted to anewmodeof administration (e.g., electronic version) [1].
Modifications that occur when an existing instrument is adapted
from paper to an electronic platform (e.g., handheld computer,
touch-screen tablet computer, or telephone-based interactive voice
response [IVR] system) include changes in thewording or placement
of instructions, wording or order of the items and/or their response
options, length of a visual analog response scale, as well as adapta-
tion from visual cognitive processes to aural cognitive processes.
This latter modification, specific to telephone-based administration
* Address correspondence to: J. Jason Lundy, Assistant Director, P
River Road, Tucson, AZ 85718-5893, USA.
E-mail: jlundy@c-path.org.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.modes, may constitute one of the more significant departures from
the original paper-based mode of administration.
Telephone-based voice/aural devices are commonly referred
to as IVR systems. Touch-tone response, not voice, however, is the
primary response option currently used [2]. IVR systems interact
with callers using a prerecorded voice question and response sys-
tem. Some of the advantages of IVR systems are that no additional
hardware is required for the respondent other than a telephone,
little if any respondent training is necessary, and data are stored
directly to the central database. In addition, because there is evi-
dence that hearing (i.e., receptive) vocabulary routinely surpasses
written vocabulary, the use of recorded voice promptsmay reduce
the literacy skill requirements of study participants [3,4].
There is a lack of peer-reviewed literature addressing themea-
surement equivalence of IVR-based versions with the original pa-
per-based, self-administered versions of commonly used PRO
questionnaires. A number of studies have been published, some of
which provided support for the reliability and feasibility of the
data collection mode, but did not involve comparisons of the IVR
responses with paper-based versions of the same questionnaires
[5,6]. Others have reported comparisons of IVR and paper-and-
pencil versions of PRO questionnaires [7–12], but the designs
and/or analytical approaches taken in these studies were not op-
t-Reported Outcome Consortium, Critical Path Institute, 1730 E.
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and Outcomes Research ePRO Task Force’s recommendations re-
garding the evidence needed to support measurement equiva-
lence [13]. The Task Force report recommends the use of a cross-
over design with statistical tests of the mean differences and
intraclass correlation coefficients (ICC). The purpose of this re-
search was to assess themeasurement equivalence of the original
paper-based version and an IVR version of the EQ-5D, a widely
used PRO measure [14], in a manner consistent with the recom-
endations of the ePRO Task Force.
Methods
Subjects
A nonprobability sample of subjects was obtained at the Arizona
Cancer Center outpatient clinics. To qualify for inclusion, poten-
tial subjects were at least 18 years of age and currently in treat-
ment (for cure or palliation) for cancer. Treatment included che-
motherapy, radiation, a combination of both, or other medical
treatments. Recruiting from among cancer patients who were un-
dergoing treatment was intended to allow greater generalizability
to patient populations participating in cancer clinical trials. Fur-
ther, the subjects must have had access to and the ability to use a
touch-tone telephone, as well as an understanding of written and
spoken English.
Over a 6-month period (December 2007 through May 2008),
project staff recruited potential subjects from the waiting areas of
the cancer center’s medical and radiation oncology outpatient
clinics. Recruitment materials emphasized the importance of this
type of research in enabling clinicians and researchers to more
effectively obtain patients’ perspectives regarding the impact of
cancer and its treatment on their lives. Interested individuals had
the opportunity to enroll based upon face-to-face contact with a
recruiter at the clinics. Also, individuals who learned about the
study from flyers were able to enroll by calling a dedicated tele-
phone line. The study was conducted under the auspices of the
University of Arizona’s Human Subjects Protection Program. All
subjects who agreed to complete the study questionnaires re-
ceived a $20 gift card.
Study design
A randomized crossover designwas utilized in this study. Respon-
dents were randomly assigned to complete either a paper ques-
tionnaire or the IVR-based questionnaire for the first administra-
tion and then the other mode for the second administration.
Testing and order effects are threats to the validity of this design,
but the within-patient design (i.e., subjects as their own control)
provides greater statistical power and decreases sample size re-
quirements. Therefore, the time between administrations should
be adequate to minimize testing effects, or carryover, from the
first administration, but not so long that the underlying do-
mains beingmeasuredmight actually change. Because the sam-
ple consisted of cancer patients receiving active treatment, the
administration interval was chosen to be 48 to 72 hours. De-
pending on the stability of the constructs being measured, a
retest interval between 2 and 14 days is generally used [15]. Our
specific administration interval was selected to minimize the
potential for the patient’s underlying health status to change,
which would threaten the validity of this study design.
After random assignment, a suitably prepared study packet
was mailed to each participant. The packet contained a cover let-
ter, a study information sheet, the study disclaimer form, and two
sealed envelopes labeled “1” and “2.” Each of these two envelopes
was labeled with the date on which they were to be opened for
self-administration of the questionnaire. The two administrationswere scheduled, in consultation with the subject, two days apart
during a relatively stable phase of their course of treatment. The
subjects were contacted on the day of the first scheduled admin-
istration to remind or confirm completion of the first question-
naire and encourage them to complete the second.
Each envelope contained information regarding completion of
the designated mode of administration. The envelope instructing
participants to complete IVR administration included written in-
formation regarding accessing the IVR system using their home
telephone. The envelope instructing participants to complete the
self-administered paper version of the questionnaire contained a
self-addressed postage-paid return envelope. The cover letter
asked the subject to complete the paper questionnaire and mail it
back upon completion.
If there was a delay in receipt (via mail) or completion (via IVR)
of the questionnaire project staff called to inquire about any diffi-
culties the subjectmay be encountering and/or to confirm that the
subject was fully aware of the study protocol timelines and en-
courage completion of the tasks. Each subject self-reported the date
of completion of the paper questionnaire, whereas the IVR system
captured the exact time and date of completion of the IVR question-
naire. The recorded dates were compared against the scheduled
completion dates for confirmation that the questionnaire was com-
pleted within the 72-hour administration window.
Study measures
During the recruitment and enrollment process, information was
obtained from subjects regarding year of birth, sex, cancer diagno-
sis (i.e., cancer site/type), and type of treatment (i.e., chemother-
apy, radiation, or a combination of both). The questionnaire,
which included the EORTC QLQ-C30 along with the EQ-5D, took
about 10 to 15 minutes to complete each time.
EQ-5D
The EQ-5D self-report questionnaire consists of two parts: a de-
scriptive system and a visual analog scale [14]. The descriptive
system comprises the following five dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression.
For each dimension, respondents are asked to describe their own
health with respect to three levels, reflecting “no problems,”
“some problems,” and “extreme problems.” These responses are
used to classify the respondent into one of 243 unique EQ-5D
health states. A scoring function assigns a value to self-reported
health states from a set of preference weights that have been em-
pirically derived [16]. The resulting EQ-5D index score is on a scale
where 1.0 represents perfect health and 0.0 represents death.
In addition to the multidimensional descriptive system, the
EQ-5D has a visual analog scale (EQ VAS) to measure the respon-
dent’s overall self-assessed health status. The original EQ VAS is a
thermometer-like 20-cm vertical line with endpoints labeled
“worst imaginable health state” and “best imaginable health state”
anchored at 0 and 100, respectively. The EQ-5D descriptive system
was adapted to the IVR using the exact wording for the items and
responses. For the EQ-VAS, the IVR system asked the respondent
to “picture in your mind” a scale with 100 at the top (i.e., “best
health state you can imagine”) and 0 at the bottom (i.e., “worst
health state you can imagine”) and enter a number between 0 and
100 that reflects his or her health status “today.”
Data analysis
Descriptive statistics of cancer type, age, and sex were calculated
to characterize the sample; no subgroup analyseswere performed.
All statistical analyses of the EQ-5D data were performed using
SPSS version 16.0 (Chicago, IL) and evaluated using a one-sided
alpha () level of 0.05.
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869V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 6 7 – 8 7 1Mean differences. Testing of the mean differences was based on
analysis of variance (i.e., split-plot analysis of variance) with fac-
tors for mode, period of administration (first or second), and sub-
ject; the P values from the significance tests will be reported. The
split-plot analysis of variance also accounts for the interaction
effect (period mode effect, often called carryover). We included
the period effect since it accounts for learning or any other period
effects as described in Hills and Armitage [17] and because we had
no a priori evidence that it could be ignored. The adjusted mean
differences between modes were estimated together with the as-
sociated 95% confidence interval (CI) for the difference. Equiva-
lence on this measure was considered to have been established if
the 95% confidence interval excludes theminimally important dif-
ference (MID) used in the sample size calculations, namely 0.07 for
the EQ-5D index and six points for the EQ VAS. Thus, the equiva-
lence intervalswere0.035 to0.035 for the EQ-5D index and3.0
to 3.0 for the EQ VAS [18,19].
Reliability. To analyze the reliability or reproducibility of themea-
surement between modes, the analyses were based upon the ICC
[20]. The ICC is calculated based on the analysis of variancemodel
that includes factors for mode and subject; the analysis is the
same regardless of whether mode is treated as a fixed or random
effect. A one-sided 95% CI for the lower bound was computed
using the formula provided in McGraw and Wong [21]. Measure-
ment equivalence was considered to have been established if the
lower bound of the 95% CI exceeded 0.70 [22].
Sample size considerations
The sample size for this study was based on two different calcu-
lations providing the sample size for testing mean differences as
well as determining the magnitude of the ICC. The sample size
calculations used for the test of mean differences comes from
Lachin [23], whereas the sample size for the ICC analyses is based
on the estimation of the magnitude of the reliability coefficient
from Streiner and Norman [15]. The resulting sample sizes based
n the calculations in Lachin [23], for a 95% CI, were 50 subjects for
he EQ-5D index and 70 subjects for the EQ VAS. The sample size
alculation to test the ICC from Streiner and Norman [15] was 108
ubjects. It is important to note that the sample size calculations
rovide the number of completed pairs necessary for the desired
tatistical power.
The more conservative sample size calculation, which is pro-
ided from the computation of the sample requirements for our
ests of the ICC, was used as the target sample size. Opting for the
igher sample size provided sensitivity around the Lachin [23] cal-
culations and also provided a large enough sample size to allow for
dropouts and incomplete data. Hence, we targeted 110 subjects for
recruitment into this study.
Results
Sample characteristics
A total of 184 subjects agreed to participate. Of those, 139 subjects
completed both administrations for a response rate of 75.5% (see
Figure 1). This sample of respondents was 67.6% female and had a
mean age of 61.5 years. The ages ranged from 19 to 86 years. Fur-
thermore, 37.4% (n  52) of this sample reported a diagnosis of
reast cancer, 17.3% (n  24) reported a diagnosis of lung cancer,
11.5% (n  16) reported a diagnosis of colorectal cancer and 7.9%
(n  11) reported a diagnosis of prostate cancer. The remaining
ancer types (n 36) included eight cases of melanoma, five cases
ach of ovarian cancer and lymphoma, and 18 diagnoses of other
ancer types. The predominant treatment for this sample was
hemotherapy (n  100, 71.9%) whereas 12.2% were receiving ra-iation therapy (n 19) and eight subjects had undergone surgery
5.8%). All other subjects (n  12) were receiving other treatment
strategies (e.g., hormones).
Data quality
The amount of missing and unusable data from the paper and IVR
administrations was tabulated for all subjects who completed
both questionnaire administrations. Of the 139 paper responses,
only twomissing responses, from the same subject, were noted on
the descriptive system. Similarly, only two missing responses
were observed, from different subjects, on the IVR version of the
descriptive system. The IVR version allowed people to actively skip
questionsbypressing the9keyon the telephonekeypad.Therewere
four subjects out of the 139 (2.9%)whodid not complete the paper EQ
VAS in contrast to nomissing data on the IVR version of the EQ VAS.
Further, there were 53 subjects (38.8%) who did not complete the
paper EQ VAS according to the instructions. Twenty-four subjects
(17.3%) drew a line from the bottom of the VAS scale (i.e., originating
from“0”) to thepoint representing the valuationof their health. Thir-
teen subjects (9.4%) drew a circle around the corresponding VAS re-
sponse and an additional 13 subjects drew a line across the VAS to
select their value. Three other unusual responses were noted: two
subjects drew an arrow pointing to their VAS response and one sub-
ject placed an “X” on the scale.
Although no missing responses were noted on the IVR version
of the EQ VAS, this mode was not free of unusual phenomenon.
There were eight subjects who entered a single-digit response on
the IVR EQ VAS. Four of those single-digit responses corresponded
exactly with the first digit of the two-digit VAS response given on
paper. For example, a subject may report an EQ VAS score of 70 on
the paper version but the IVR version scorewas recorded as a score
of seven. Two subjects reported paper VAS scores of 70 and 40 but
the corresponding IVR scores were eight and five, respectively. Of
the remaining two subjects, one subject did not respond to the
paper VAS and the other subject had very disparate scores of a 40
on the paper and a five on the IVR version.
Equivalence testing
The analyses for the index score and the EQ VAS were based on a
per protocol analysis. Hence, subjects were in the analyses if they
completed both questionnaire administrations within 72 hours,
which, based on the study protocol, was the maximum amount of
time for completion of the two administrations including the in-
tervening day. Furthermore subjectswere excluded from the anal-
ysis if their score difference exceeded two standard deviations
Fig. 1 – Sample characteristics. IVR, interactive voice
response.(95% of the score distribution), namely 40 points on the EQ VAS
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870 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 6 7 – 8 7 1and 0.28 on the EQ-5D index score. The analysis included 109 sub-
jects for the EQ VAS and 113 subjects for the index. Of the 30 EQ
VAS exclusions, 21 subjects were beyond the 72-hour completion
window, four subjects had missing EQ VAS scores, and five sub-
jects had scores considered outliers (all five subjects exhibited the
single digit phenomenon). Of the 26 subjects excluded from the
EQ-5D index analysis, 22 subjects were beyond the 72-hour com-
pletion window, two subjects had missing index scores, and two
subjects had scores considered outliers.
The means of the paper and IVR administrations of the EQ-5D
index were 0.790 0.172 and 0.800 0.180, respectively. The tests
or an order effect and for an order by mode interaction based on
he split-plot analysis of variancewere not statistically significant.
he adjusted means (i.e., least squares means) were 0.789  0.016
or the paper version and 0.798  0.017 for the IVR version. The
djusted mean difference was -0.009 and the 95% CI of the mean
ifference was 0.024 to 0.006, which was within the equivalence
nterval. The ICC was 0.894 (95% lower CI 0.857), significantly
reater than 0.70 (Table 1). Furthermore the percent of exact agree-
ent and kappa coefficients for each of the five dimensions of the
escriptive system are provided in Table 2.
The EQ VAS means were 71.9  19.7 for paper and 74.6  18.7
or IVR. There was no order effect present; however, there was a
ignificant mode by order interaction in the analysis of means for
he EQ VAS (P  0.022). The adjusted means were 71.94  1.87 for
he paper and 74.63  1.79 for the IVR. The adjusted mean differ-
nce was 2.69  0.83 and associated 95% CI of the mean differ-
nce was 4.347 to 1.049, partially contained within the equiva-
lence interval of 3 to 3. The ICC was 0.887 (95% lower CI 0.830)
also significantly greater than 0.70 (Table 1).
To assess the robustness of our “per protocol” analyses, we
included subjects who were removed because their score differ-
ence exceeded two standard deviations between administrations.
We did not include those who were outside the administration
window of 72 hours. Due to the nature of our cancer patient sam-
ple, a change in the underlying health condition of the subjects
was a key threat to the internal validity of the study. Hence, the
administration window was specified a priori to mitigate this ef-
fect and ensure a stable sample for equivalence testing. In an anal-
ysis of all completed score pairs within the 72-hourwindow on the
EQ-5D index (n  115), the adjusted mean difference was 0.014
(0.002 to 0.030) and the ICC was 0.873 (95% lower CI 0.821). A
similar analysis of EQ VAS responders (n  114) yielded an ad-
usted mean difference of 0.53 (1.99 to 3.05) and an ICC of 0.803
95% lower CI 0.727).
Discussion
The results of the comparison of the paper version of the EQ-5D
Table 1 – Mean differences and intraclass correlation
coefficients (ICCs) for the EQ-5D scores.
Adjusted
means (SE)*
Mean difference
(95% CI)
ICC
(95% lower CI)
Paper EQ-5D
index
0.789 (0.016) 0.009 (0.024 to 0.006) 0.894 (0.857)
IVR EQ-5D
index
0.798 (0.017)
Paper EQ
VAS
71.94 (1.87) 2.69 (4.347 to 1.049) 0.887 (0.840)
IVR EQ VAS 74.63 (1.79)
CI, confidence interval; IVR, interactive voice response; SE, standard
error; VAS, visual analog scale.
* Adjusted means are equivalent to least squares means.with the IVR version provide substantial evidence supporting themeasurement equivalence of these two modes of administration.
However, these results do have limitations, including a study sam-
ple that may lack generalizability to the general population, the
cancer patient population, and patients with other conditions or
diseases. Because the internal validity of measurement equiva-
lence studies is of greater importance, we felt this was an accept-
able tradeoff. For measurement equivalence studies, the preser-
vation of internal validity to detect evidence of the introduction of
systematic bias is of foremost importance. Although the possibil-
ity of these findings being sample-dependent remains, the choice
of sample is unlikely to have a large impact on determining
whether bias was introduced when migrating from paper to IVR.
Therefore, whereas the magnitude of the scores is not generaliz-
able to other populations, the lack of systematic differences be-
tween the paper and IVR version of the EQ-5D may transcend the
sample from which it resulted. In addition, because only a US-
English language version of the EQ-5D was used in this study,
measurement equivalence of other language or cross-cultural
translations of the EQ-5D remains unassessed.
Further, we encountered a small amount of unusable data from
the IVR version of the EQ VAS. We observed the phenomenon of a
subject entering a single digit (i.e., “8”) upon one administration and
having a value of 70 on the other administration. We believe it is
unlikely that subjects intended such a wide disparity when evaluat-
ing their current health status, particularly over the 2- to 3-day inter-
val used in this study. Although the disparate values were only ob-
served in eight subjects (5.7%), this situation resulted in unreliable
data provided by the electronic platform. To overcome this limita-
tion, we recommend that when items with response sets exceeding
single digits (e.g., EQ VAS) are adapted to IVR systems, that the sys-
tem prompts the subject to confirm his or her choice. This solution
could be easily incorporated and should eliminate this problem.
Finally, although not a part of our original analytic plan, we
conducted analyses that included all completed score pairs within
the 72-hour administration window for the EQ-5D index and EQ
VAS. Due to the inclusion of additional sources of variance, the
results demonstrate lower levels of score agreement; however,
they do not change the conclusions of this study. The results re-
inforce the need to carefully specify the per protocol criteria, a
priori, in an attempt to limit sources of variability that may result
from study design considerations when testing measurement
equivalence.
By using a crossover design and tests of mean differences and
ICCs, our study and analytical strategy conformed to the recom-
mendations of the International Society for Pharmacoeconomics
and Outcomes Research ePRO Task Force regarding the evidence
needed to support measurement equivalence [13]. The mean dif-
ference CI for the EQ-5D index score reflected equivalence of the
means from the twomodes, as the CI was wholly contained inside
the equivalence interval. The mean difference CI for the EQ VAS
was only partially contained in the equivalence interval, providing
an inconclusive result of either equivalence or nonequivalence of
the mean EQ VAS scores. However, it is worth noting that others
Table 2 – Percent agreement and kappa coefficients for
the five EQ-5D dimensions.
EQ-5D
dimension
Percent
exact
agreement
Kappa (SE)
Mobility 81.3% 0.657 (0.074)
Self-care 95.0% 0.761 (0.115)
Usual activities 79.1% 0.650 (0.065)
Pain/discomfort 84.9% 0.721 (0.064)
Anxiety/depression 86.3% 0.746 (0.059)SE, standard error.
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ently in the literature [24,25]. For instance, in a study assessing the
measurement equivalence of English and Chinese versions of the
EQ-5D, Luo et al. [24] used smaller MIDs than we did for the EQ-5D
ndex (0.05 vs. 0.07) and the EQ VAS (5.0 vs. 6.0); however, they
perationalized their equivalence intervals as 0.05 to 0.05 for
he EQ-5D index and -5.0 to5.0 for the EQVAS. Hence their equiv-
lence intervals were double their MIDs, whereas our equivalence
ntervalswere equal inmagnitude to our chosenMIDs. In addition,
oth the index and EQ VAS scores in our study had ICCs or kappa
oefficients that were on par or higher than those observed in the
iterature for the test–retest comparison of the paper version.
As stated in the ePRO Task Force recommendations, electronic
odes of administration should not be held to a higher standard
han the original paper-based version [13]. Although limited, some
ata are available regarding within-mode (i.e., paper to paper) test-
etest results for the EQ-5D, Macran [26] reports reliability coeffi-
cients for the EQ-5D descriptive system (i.e., dimensions) and the EQ
VAS for two different test-retest paper administrations with a
3-month interval. The first study used data collected in theMeasure-
ment and Valuation of Health study and reported kappa coefficients
that ranged from0.49 to 0.75 on the descriptive systemand an ICC of
0.84 on the EQVAS. The second analysis from a rheumatoid arthritis
study reported kappas on the five dimensions that ranged from 0.40
to 0.65 and an ICC of 0.78 for the EQ VAS. The kappas from our study
were mostly higher and from a smaller range, albeit from a much
shorter time interval. The ICCs for theEQVASwerehigher than those
reported by Macran [26]. Moreover, there were substantial percent-
ages of absolute agreement, above 79% on all dimensions, between
the paper and IVR versions of the EQ-5D.
Conclusions
This study compared the scores derived from paper and IVR ver-
sions of the EQ-5D in a sample of cancer patients. The evidence
presentedhere,when taken in totality, supports themeasurement
equivalence of the IVR version of the EQ-5Dwith the original paper
version. Investigators should have confidence that the scores ob-
tained from the IVR version of the EQ-5D are comparable to those
obtained on the paper version.
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